OTHERS APPOINTMENT BY ENIMMUNE CORPORATION OF DUOPHARMA (M) SENDIRIAN BERHAD, A WHOLLY — OWNED SUBSIDIARY OF DUOPHARMA BIOTECH BERHAD, AS THE EXCLUSIVE DISTRIBUTOR OF ENTEROVIRUS EV71 MONOVALENT VACCINE IN MALAYSIA, SINGAPORE AND BRUNEI

Others Appointment By Enimmune Corporation Of Duopharma (M) Sendirian Berhad, A Wholly-owned Subsidiary Of Duopharma Biotech Berhad, As The Exclusive Distributor Of Enterovirus Ev71 Monovalent Vaccine In Malaysia, Singapore And Brunei Duopharma Biotech Berhad Type Announcement Subject OTHERS Description APPOINTMENT BY ENIMMUNE CORPORATION OF DUOPHARMA (M) SENDIRIAN BERHAD, A WHOLLY-OWNED SUBSIDIARY OF DUOPHARMA BIOTECH BERHAD, AS THE EXCLUSIVE DISTRIBUTOR OF ENTEROVIRUS EV71 MONOVALENT VACCINE IN MALAYSIA, SINGAPORE AND BRUNEI Duopharma Biotech Berhad (hereinafter referred to as "Duopharma Biotech" or the "Company") wishes to announce that, Duopharma (M) Sendirian Berhad (hereinafter referred to as "DMSB") (a wholly-owned subsidiary of Duopharma Biotech) has on 15 October 2026 entered into a Supply Agreement with Enimmune Corporation ("Enimmune") whereby DMSB has been appointed as the exclusive distributor of enterovirus EV71 monovalent vaccine or 'EnVAX-A71 Vaccine' (hereinafter referred to as the "Product") in Malaysia, Singapore and Brunei (hereinafter collectively referred to as the "Territory"). The aforesaid Supply Agreement is in the ordinary course of business of the Duopha